The National Institutes of Health, National Institute of General Medical Sciences, is accepting applications for Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 – Clinical Trial Not Allowed), opportunity PAR-27-055, Assistance Listing 93.859.
The program supports expansion and long-term sustainability of biomedical research capacity at qualifying institutions in IDeA jurisdictions. COBRE-E supports growth of research programs, faculty, and core facilities. COBRE-S supports continued development and consolidation of the infrastructure created in prior COBRE phases.
Next application deadline: September 25, 2026 at 5:00 PM local time of the applicant organization. Additional receipt dates recur on January 25, May 25, and September 25 through May 25, 2029. Application budgets may not exceed $1.5 million in annual direct costs for a project period of up to five years. No cost sharing is required.
Eligible applicants are qualifying higher-education institutions and nonprofit organizations in IDeA jurisdictions: Alaska, Arkansas, Delaware, Hawaii, Idaho, Kansas, Kentucky, Louisiana, Maine, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Puerto Rico, Rhode Island, South Carolina, South Dakota, Vermont, West Virginia, and Wyoming. Eligible institutions must award doctoral degrees in health-related sciences or be independent biomedical research institutes or medical centers with ongoing federally funded biomedical research and must hold three or fewer active COBRE awards.
COBRE-E applicants must possess existing research capacity that can be allocated to the proposed scientific area or hold an active COBRE Phase 1 or COBRE-D award. COBRE-S applicants must hold an active COBRE Phase 2 or COBRE-E award. PDs/PIs must meet NIH leadership, appointment, and externally funded research requirements. Required registrations include SAM.gov/UEI, Grants.gov, eRA Commons, and ORCID. Applications are submitted through NIH ASSIST or an institutional system-to-system solution to Grants.gov and tracked in eRA Commons.
The opportunity does not allow clinical trials. It does, however, support research-core facilities, acquisition of new equipment, modernization of instrumentation, and maintenance of state-of-the-art technologies. This creates a legitimate conditional role for the Nonagon N9+ device and platform where the approved center scientific area needs shared non-interventional physiological measurement, guided examination, remote or telehealth-enabled observational research, translational data capture, or related capabilities.
Atlas assigns an Atlas Opportunity Score of 91/100 and an N9+ Fit Score of 82/100. The fit is conditional on the specific scientific area and the institution’s COBRE phase eligibility. Dr. Miltie, LLC is not eligible to serve as the prime applicant, so any role would be partner- or vendor-led under the eligible institution’s approved program and procurement rules.